MedAdvisor Projects Revenue Boost in Second Half of FY25
MedAdvisor Limited (AU:MDR) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
MedAdvisor Limited anticipates a notable shift in revenue from the first half to the second half of FY25 due to lower-than-expected flu vaccination rates in the US. While the company’s Australian operations remain stable, MedAdvisor is counting on a diverse and strong second-half pipeline in the US to boost revenue. The company remains optimistic about a record-breaking second half, attributing this to strategic diversification efforts.
For further insights into AU:MDR stock, check out TipRanks’ Stock Analysis page.
Trending Articles
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.